CG
ALDR

Cutler Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Cutler Group’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-61,600
Closed -$10K – 4975
2019
Q3 		$10K Buy
+61,600
New +$705K ﹤0.01% 2657
2018
Q1 		– Sell
-17,400
Closed -$46K – 5675
2017
Q4 		$46K Sell
17,400
-9,000
-34% -$100K ﹤0.01% 1939
2017
Q3 		$70K Sell
26,400
-26,100
-50% -$272K ﹤0.01% 1953
2017
Q2 		$222K Buy
52,500
+45,800
+684% +$847K 0.01% 1194
2017
Q1 		$10K Buy
6,700
+3,400
+103% +$75.3K ﹤0.01% 4099
2016
Q4 		$16K Sell
3,300
-14,100
-81% -$367K ﹤0.01% 3727
2016
Q3 		$11K Buy
17,400
+7,800
+81% +$238K ﹤0.01% 4166
2016
Q2 		$34K Sell
9,600
-12,900
-57% -$349K ﹤0.01% 2776
2016
Q1 		$81K Buy
22,500
+10,300
+84% +$238K 0.01% 1827
2015
Q4 		$24K Buy
+12,200
New +$413K ﹤0.01% 3243

Cutler Group's ALDR Position: Q4 2019 in Review

Cutler Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 1,500 shares — an estimated $28K sold.

Cutler Group first reported a position in ALDR in Q4 2015 and held it in 11 quarters. The position peaked at $492K in Q2 2017. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

  • Cutler Group reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Cutler Group sold 1,500 Alder Biopharmaceuticals shares in Q4 2019, an estimated $28K.
  • Cutler Group first reported a position in Alder Biopharmaceuticals in Q4 2015 and held it in 11 quarters.
  • Cutler Group's Alder Biopharmaceuticals position peaked at $492K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Cutler Group's 13F filing for Q4 2019, filed 6 Feb 2020.